profile

Non-conventional yeast in the wine industry
Submit Manuscript on this topicIndexed Articles
Description
The wine industry is increasingly demanding new sensory characteristics, biotechnological applications and differentiation of the products. The use of culture starters has increased the control of the process although, due to the limited diversity of starters, has introduced also some uniformity in the wine industry. Wine microbiology is giving an answer to these demands through the use of non-conventional microorganisms that can provide some of the required changes in the wine production. This Research Topic aims to update the late developments in the field of the use of non-conventional yeasts (both non-Saccharomyces as well as non-S. cerevisiae) applied to the wine industry.
Thus, this Research Topic can focus on:
- Ecological studies to find species with wine making potential, including next generation sequencing.
- Improvement of present methodology for the identification and typing of non-conventional yeasts.
- Use of non-conventional yeast for improving sensory properties of wines
- Use of non-conventional yeast for improving technological processes
- Increase of terroir typicity: microbial fingerprinting and footprinting
- Reduction of acidity, ethanol, etc…
- Industrial adaptation of non-conventional yeast (drying, user-friendly preparations,…)
- Metabolic and genomic studies of non-conventional yeast.
Journal Recent Articles
Helpful Links
- Publication Ethics
- Peer Review
- Open Access
- Author Guidelines
- Editor Guidelines
- Reviewer Guidelines
- Terms & Conditions
CONTACT US
80 Maiden Lane,
Floor Water Street Corridor,
New York, NY 10038
Call Us:
JOURNALS LINKS
Recent Articles Indexed
- Comparing a Neutropenic Diet to a Food Safety-Based Diet in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation.
- A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study.
- A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study.
- Home vs Hospital Infusion of Biologic Agents for Patients With Inflammatory Bowel Diseases.
- Hepatitis C virus and mortality among patients on dialysis: A systematic review and meta-analysis.
- Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women.